Dr. Bruce Bloom is the President and Chief Science Officer of Cures Within Reach. His journey to this position started in February 2002, when he became the Executive Director of Goldman Philanthropic Partnerships, a 501(c)(3) private operating foundation. In 2005, when Goldman Partnerships created the public charity Partnership for Cures to carry on the Goldman mission, Dr. Bloom became President and Chief Science Officer. In October 2012, Partnership for Cures changed its name to Cures Within Reach to better reflect the focus of its mission: repurposing drugs and other treatments to drive more treatments to more patients more quickly. Dr. Bloom directs the operation of this public charity dedicated to improving patient quality and length of life by facilitating pilot clinical trials testing repurposed treatments designed to be immediately incorporated into clinical use. Cures Within Reach’s newest venture is CureAccelerator™, the only global online repurposing research collaboration platform designed to bring together funders, clinicians, researchers, industry and lay stakeholders to create and conduct pilot clinical trials that drive more repurposed treatments to more patients more quickly.

1. Repurposing Research Clinical Trials
HX Refactored 2016 Boston
Dr. Bruce E. Bloom
President and Chief Science Officer
Cures Within Reach

2. W W W & H?
• Why I am here
• Who we are
• What types/phases of clinical trials
• How repurposing clinical trials arise
• What are our success stories
• What are clinical trial issues/challenges
• What are current/future trials changes

3. Cures Within Reach is a non-profit that works to catalyze repurposing
research to quickly and affordably improve patient lives. Repurposing
research seeks to create new treatments for serious unmet needs using
existing drugs, devices and nutriceuticals.
We accomplish this through collaborations that connect researchers and
funding, by facilitating crowd sourcing, building community and by
identifying alternative financing models and incentives.

4. Repurposing vs. de novo research

5.  Over 40 Academic research
institution partners
 23 projects currently in
process
 Focus on late pre-clinical or
pilot clinical proof of concept
 13 CWR repurposed
treatments in use by patients
today.

6. Phases of clinical trials
•Phase I-safety
•Phase II-controlled population efficacy
•Phase III-wider population efficacy
•Phase IV-post marketing surveillance

7. Types of Trials

9. Origin of Repurposing Clinical Trials
•Discovery about a disease
•Discovery about a therapy
•Clinical observation/co-morbidity
•Off-label use/patient insight
•Systematic screening

10. Generic
Drug
DevicesChange in
Therapy
Nutriceuticals
Successful CWR repurposing clinical trials

11. Generic drug saves
lives of kids with rare
auto-immune disease
6 patients clinical
trial delivers life-
saving treatment
Total $250K
3 years
Endpoints Always
Matter
Size DOESN’TAlways
Matter
Led to 5 additional
clinical trials repurposing
same drug

12. Change in therapy
improves success of
ASCT by 40% in rare
blood cancers
Could affect 600,000 patients
worldwide each year
Total $600K grant over
5 years
Clinical Trials
to Validate
Clinical Observations
Serendipity plus curiosity
plus persistence
Started with NHL-
Then applied to MM
and other blood cancers

13. $1M 7 years
6 repurposed
nutriceuticals create
100% protein levels
Supplement combo
“cures”
Familial Dysautonomia
Nature’s
“drugs”
The fastest,
cheapest way
to a new
treatment
No clinical trial
required!

14. Laser device repurposed for
prostate cancer treatment
eliminates side effects
$50K CWR pilot $500K NIH grant
for Phase III trial. Device moving
into SOC at major institutions
Device+PT
restores lost
function-MS
$50K CWR pilot
$4M for 510K
FDA approval
Don’t
Overlook
Devices
Faster path to
commercialization

15. Current CWR repurposing clinical trials
Phase III clinical
trial repurposing
BCG
Common
disease
Rare disease
repurposing
with CIHR
Cross border
co-PIs
Generics
Repurposing
England
New SIB economic
engine-pay for
success model
Open Source
Pharma
Foundation
Repurposing for
neglected disease
of poverty

16. Promoting
Repurposing
Collaboration

17. Created by
Cures Within
Reach
Launched in
June 2015
Platform built
with a grant
from the Robert
Wood Johnson
Foundation
The world’s first online,
interactive platform dedicated
to repurposing research,
testing new treatments for
unsolved diseases using
existing drugs and devices

18. Since
November 2015
Over
120 projects
submitted
From
52 Institutions
In
7 Countries
Oncology-45 Neuro-20
Rare diseases-23 Infectious-6
Autoimmune-6 Pediatric-5
Hematology-4 Cardiology 4
Ophthalmology-3 Pulmonary-2
GI-1 Nephrology-1

19. Multiple Stakeholder Participation

21. Future of repurposing clinical trials
•Virtual clinical research
•“Big Data” retrospective studies
•Prospective observational studies
•Clinical trial crowd research-tech driven

22. Join us
1. Register for CureAccelerator™
https://app.cureaccelerator.org/registration
1. Log in and start a digital discussion, post an RFP or post a
project
1. Encourage your research institution, biotech or disease
specific non-profit to become a CureAccelerator partner

23. To learn more
Dr. Bruce Bloom
Bruce@cureswithinreach.org
847-745-1245
www.cureswithinreach.org
www.cureaccelerator.org
Cures Within Reach is a 501(c)3 non-
profit organization, tax ID 20-3620169